The closure of recruitment into Futura’s pivotal trial of Eroxon® (the company’s topical treatment of Erectile Dysfunction) is a positive development that provides a firm timeline for the expected release of headline data in Q3 (from Q2). The strategy for commercialising the product (beyond the UK Specials programme with Quantum Pharma) will be based on the trial outcome. As we highlighted in our note ‘Eroxon® data ahead’ on 5th April, the product could drive significant valuation upside subject ....
04 May 2016
Recruitment closed in Eroxon® trial
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Recruitment closed in Eroxon® trial
Futura Medical plc (FUM:LON) | 36.0 0.2 1.5% | Mkt Cap: 108.4m
- Published:
04 May 2016 -
Author:
Dr Jens Lindqvist -
Pages:
3
The closure of recruitment into Futura’s pivotal trial of Eroxon® (the company’s topical treatment of Erectile Dysfunction) is a positive development that provides a firm timeline for the expected release of headline data in Q3 (from Q2). The strategy for commercialising the product (beyond the UK Specials programme with Quantum Pharma) will be based on the trial outcome. As we highlighted in our note ‘Eroxon® data ahead’ on 5th April, the product could drive significant valuation upside subject ....